In this episode of the Applied Clinical Trials Podcast, C.K. Wang, MD, chief medical officer at COTA; and Sujay Jadhav, CEO ...

In today’s ACT Brief, we explore how Bayesian trial designs are gaining traction in rare disease research, what priorities clinical operations leaders should focus on in 2026, and how rare disease ...

As rare disease trials face persistent feasibility challenges, Bayesian designs are gaining momentum by enabling more ...

Jonathan Andrus, co-CEO of CRIO, discusses how increased reliance on site-based technologies and eSource is strengthening ...

Jonathan Andrus, co-CEO of CRIO, explains how protocol-driven eSource templates and standardized data capture are improving consistency, oversight, and efficiency across clinical trial sites.

Andrus: The biggest risk is fragmented, disconnected data collection across sites. If you think about a large phase 3 trial ...

In today’s ACT Brief, we examine how protocol-driven eSource is reshaping data capture at sites, how digital protocols and ...

In today’s ACT Brief, we examine how site-level data capture is becoming central to trial execution, how Merck and Mayo ...

As clinical development grows more complex, sponsors are rethinking how outsourcing models, technology, and partnerships align to support both speed and sustainability. The shift toward hybrid models, ...

In today’s ACT Brief, we explore how sites are taking the lead on AI adoption to strengthen feasibility and enrollment, why earlier cross-functional alignment is critical in data-driven trials, and ...

In a new FAQ article on ACT, evolving outsourcing strategies reflect growing demand for flexibility as trial complexity increases. Hybrid models that blend full-service and functional approaches are ...

At SCOPE Summit 2026, site leaders shared how AI is transforming feasibility, patient identification, and enrollment strategies, enabling research sites to boost performance, strengthen sponsor ...